RESUMEN
INTRODUÇÃO: A doença falciforme (DF) compreende um grupo de anemias hemolíticas hereditárias cuja principal característica é a presença do gene da hemoglobina S (Hb S) que pode combinar-se com outras anormalidades sanguíneas hereditárias. O quadro clínico varia desde quase assintomático até formas graves. A Hidroxiuréia (HU) é a terapia de maior sucesso. É uma doença crônica, cuja prevalência e morbidade são altas no Brasil, dessa forma a qualidade de vida (QV) surge como um importante desafio para os pacientes, familiares e profissionais de saúde. OBJETIVOS: Avaliar a QV de pacientes portadores de DF, suas características sociodemográficas e clínicas. MÉTODOS: Os dados foram coletados através do questionário de QV abreviado (WHOQOL-Bref), questionário sociodemográfico e prontuário clínico. RESULTADOS: foram entrevistados 39 pacientes, entre 18 e 54 anos, tratados na Fundação Hemominas em Divinópolis - MG. A maioria dos pacientes eram homens (56%), homozigotos para a Hb S (80%), solteiros (67%), segundo grau completo (31%) e não usuários de HU (61%). Dentre os pacientes avaliados 53,8% considerou ter boa QV (escore médio 74,2 ±20,3). O escore relacionado à QV geral foi de 71,5. Os domínios físico e meio ambiente obtiveram os menores escores médio (61,5 e 59,0, respectivamente). Não foram encontradas diferenças significativas entre os que utilizavam ou não HU. CONCLUSÕES: Os pacientes com DF apresentaram boa QV, sendo mais comprometida pelos aspectos relacionados ao domínio meio ambiente, (como recursos financeiros) e físico (como dor e desconforto) que se correlacionam com as características clínicas e sociais relacionadas a DF.
Introduction: sickle cell disease (SCD) comprises a group of hereditary hemolytic anemias whose main characteristic is the presence of the hemoglobin S (Hb S) gene that can be combined with other hereditary blood abnormalities. The clinical picture ranges from almost asymptomatic to severe forms. Hydroxyurea (HU) is the most successful therapy. It is a chronic disease whose prevalence and morbidity are high in Brazil, thus quality of life (QoL) emerges as an important challenge for patients, family members and health professionals. Objectives: This study aimed to evaluate the QoL of patients with SCD, their sociodemographic and clinical characteristics. Methods: Data were collected through the abbreviated QoL questionnaire (WHOQOL-Bref), sociodemographic questionnaire and clinical chart. Results: It has interviewed at the Hemominas Foundation in Divinópolis - MG, 39 patients aged 18-54. Most of the patients were male (56%), homozygous for Hb S (80%), unmarried (67%), completed high school (31%) and non HU users (61%). Among the patients evaluated, 53.8% considered having a good QoL (mean score 74.2 ± 20.3). The overall QoL score was 71.5. The physical and environmental domains had the lowest mean scores (61.5 and 59.0, respectively). No significant differences were found among those using or not using HU. Conclusions: Patients with SCD presented good QoL, being more affected by aspects related to the environmental domain (such as financial resources) and physical (such as pain and discomfort) those correlate with clinical and social characteristics related to SCD.
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Adulto Joven , Calidad de Vida , Anemia de Células Falciformes , Dolor , Medio Social , Factores Socioeconómicos , Hemoglobinas/análisis , Encuestas y Cuestionarios , Ambiente , Anemia de Células Falciformes/psicología , Anemia de Células Falciformes/tratamiento farmacológicoRESUMEN
OBJECTIVE: This study aimed to describe and analyze clinical and laboratory characteristics of patients with sickle cell anemia treated at the Hemominas Foundation, in Divinópolis, Brazil. Furthermore, this study aimed to compare the clinical and laboratory outcomes of the group of patients treated with hydroxyurea with those patients that were not treated with hydroxyurea. METHODS: Clinical and laboratorial data were obtained by analyzing medical records of patients with sickle cell anemia. RESULTS: Data from the medical records of 50 patients were analyzed. Most of the patients were female (56%), aged between 20 and 29 years old. Infections, transfusions, cholecystectomy, splenectomy and systemic arterial hypertension were the most common clinical adverse events of the patients. The most frequent cause of hospitalization was painful crisis. The majority of patients had reduced values of hemoglobin and hematocrit (8.55±1.33g/dL and 25.7±4.4%, respectively) and increased fetal hemoglobin levels (12±7%). None of the clinical variables was statistically significant on comparing the two groups of patients. Among hematological variables only hemoglobin and hematocrit levels were statistically different between patients treated with hydroxyurea and untreated patients (p-value=0.005 and p-value=0.001, respectively). CONCLUSION: Sickle cell anemia requires treatment and follow-up by a multiprofessional team. A current therapeutic option is hydroxyurea. This drug reduces complications and improves laboratorial parameters of patients. In this study, the use of the drug increased the hemoglobin and hematocrit levels of patients.
RESUMEN
Abstract Objective: This study aimed to describe and analyze clinical and laboratory characteristics of patients with sickle cell anemia treated at the Hemominas Foundation, in Divinópolis, Brazil. Furthermore, this study aimed to compare the clinical and laboratory outcomes of the group of patients treated with hydroxyurea with those patients that were not treated with hydroxyurea. Methods: Clinical and laboratorial data were obtained by analyzing medical records of patients with sickle cell anemia. Results: Data from the medical records of 50 patients were analyzed. Most of the patients were female (56%), aged between 20 and 29 years old. Infections, transfusions, cholecystectomy, splenectomy and systemic arterial hypertension were the most common clinical adverse events of the patients. The most frequent cause of hospitalization was painful crisis. The majority of patients had reduced values of hemoglobin and hematocrit (8.55 ± 1.33 g/dL and 25.7 ± 4.4%, respectively) and increased fetal hemoglobin levels (12 ± 7%). None of the clinical variables was statistically significant on comparing the two groups of patients. Among hematological variables only hemoglobin and hematocrit levels were statistically different between patients treated with hydroxyurea and untreated patients (p-value = 0.005 and p-value = 0.001, respectively). Conclusion: Sickle cell anemia requires treatment and follow-up by a multiprofessional team. A current therapeutic option is hydroxyurea. This drug reduces complications and improves laboratorial parameters of patients. In this study, the use of the drug increased the hemoglobin and hematocrit levels of patients.